Niche Cancer Tools Neoprobe specializes in intraoperative gamma detection devices and radiopharmaceutical targeting agents to improve cancer surgery outcomes, presenting a focused entry point for surgical oncology teams and hospitals deploying real-time guidance tools.

Small Firm Advantage With a lean team and revenues in the low millions, there is potential for agile partnerships, rapid pilot programs, and high-touch customer support to establish reference installations and case studies in niche surgical centers.

Clinical Partnerships Target opportunities include collaboration with cancer centers, surgeons, and radiopharmacy departments to integrate tracing agents with detection devices, enabling bundled offerings and joint clinical evaluations.

Expansive Market Fit Benchmark peers operate at large scales; Neoprobe can position as a specialized, high-precision device supplier complementing larger medical device portfolios, appealing to hospitals seeking advanced intraoperative imaging capabilities.

Growth via Education Sales opportunities can be unlocked through clinical education programs, case studies, and training sessions that demonstrate improved margin and outcome metrics, driving adoption among surgical teams and procurement committees.